---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-043919"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2026-09-23T20:05:21+00:00"
generated_at: "2026-09-23T20:06:09.673703+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Evofem signs manufacturing deal with Zhaoke for PHEXX, targets 40%+ cost cut

## Summary
- Manufacturing agreement with Zhaoke (Hong Kong) and Zhaoke (Guangzhou) dated Sept 17, 2026.
- Expected to reduce PHEXX unit costs by 40% or more after FDA approval, improving economics.
- Plans sNDA submission to FDA in mid-2027 for PHEXX from the new facility.
- Adds second supply source to boost flexibility and capacity for US and global growth.

## SEC filing metadata
- accession: 0001493152-26-043919
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2026-09-23T20:05:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315226043919/0001493152-26-043919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315226043919/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-043919
- JSON: https://secwatch.observer/filing/0001493152-26-043919.json
- Plain text: https://secwatch.observer/filing/0001493152-26-043919.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.